31 results about "Genital Tract Infections" patented technology

The invention discloses a full-automatic genital tract infection detection system which comprises a plurality of joint inspection cards for detecting a sample, an automatic supply unit, an automatic card dispatching unit, an automatic sample injection unit, an automatic transmission unit, an automatic incubation unit, a reagent injection unit, an automatic measuring and reading unit and an electrical control unit, wherein the electrical control unit controls automatic running of all the units through software of a computer. According to the full-automatic genital tract infection detection system disclosed by the invention, due to the processes of automatic card dispatching, automatic sample injection, automatic incubation, automatic measuring and reading and the like which are controlled through the computer, manual participation steps are reduced, the measuring and reading accuracy is improved, and the test speed of detecting more than a set number of samples per hour can be achieved.

The invention relates to the technical field of biology, in particular to a novel lactobacillus gasseri strain for preventing and / or treating genital tract infection and / or genital tract flora disorder and application of the novel lactobacillus gasseri strain. In order to solve the technical problems of different degrees of side effects, high recurrence rate or large trauma and the like of the existing medicine for treating genital tract infection, the invention screens out a new lactobacillus gasseri TM13-16 for preventing and / or treating genital tract infection and / or genital tract flora disorder, which can generate secretions such as lactic acid, hydrogen peroxide and the like is used for inhibiting the growth of pathogenic bacteria of genital tract infection, is used for preventing and / or treatment genital tract infection diseases, particularly reducing the recurrence rate, has small toxic and side effects and lasting efficacy, and can be used as dominant lactobacillus for vagina to repair flora disorder and restore vaginal homeostasis.

The invention provides a Chinese medicinal preparation for treating gynecological inflammation, and relates to a Chinese medicinal preparation. The Chinese medicinal preparation solves the problems of high toxicity and high medicament resistance rate of conventional western medicaments, poor treatment effects of conventional Chinese medicaments, main concentration on prescription medication of clinical treatment, and no Chinese patent medicament capable of being widely applied to clinical genital tract infection of women and being clinically applied. The Chinese medicinal preparation is prepared from amur corktree bark, atraotydin, common cnidium fruit and dandelion. Pharmacodynamic and toxicological experiments prove that the Chinese medicinal preparation for treating the gynecological inflammation has the advantages of long-term use, safety, no toxic or side effects, antibiosis, anti-mycoplasma, good antiphlogosis effect, and good treatment effect. The Chinese medicinal preparation can be prepared into the Chinese patent medicament for the clinical genital tract infection of women, and solves the problems of main adoption of the prescription medication of clinical treatment, and no Chinese patent medicament capable of being widely applied to clinical genital tract infection of women and being clinically applied.

The invention discloses a primer group, a probe group and a kit for synchronously detecting multiple pathogens related to genital tract infection. The sequences of primer composition and probes are SEQIDNO: 1-45, and a fluorescent group and a quenching group are contained at the two ends of each sequence of the probe group. According to the kit disclosed by the invention, the kit comprises the primer group, the probe group, a pathogen marker standard solution as well as enzymes and reagents commonly used in PCR (polymerase chain reaction), can simultaneously detect 15 pathogens related to thegenital tract infection, and has the advantages of high reverse transcription efficiency, strong primer specificity, high sensitivity, comprehensive, rapid and accurate detection and wide applicationrange, and the detection result can be used for clinical diagnosis and treatment.

The invention relates to the technical field of biology, in particular to a novel lactobacillus crispatus strain for preventing and / or treating genital tract flora disorder related diseases and application of the novel lactobacillus crispatus strain. In order to solve the technical problems of different degrees of side effects, high recurrence rate or large trauma and the like of the existing medicine for treating the genital tract flora disorder related diseases, the invention screens out a novel lactobacillus crispatus LG55-27 for preventing and / or treating the genital tract flora disorder related diseases, which can generate secretions such as lactic acid, hydrogen peroxide and the like, is used for inhibiting the growth of pathogenic bacteria of genital tract infection, is used for preventing and / or treating diseases related to genital tract flora disorder, particularly reduces the recurrence rate, has small toxic and side effects and lasting efficacy, and can be used as a dominantbacterial strain of the genital tract to increase the abundance, repair flora disorder and recover vaginal homeostasis.

The invention discloses a physical contraceptive gel film-forming agent without a spermicide, which comprises the following components in percentage by weight: 1 to 3 percent of chitosan, 0.5 to 3 percent of a thickening agent, 5 to 15 percent of glycerol and propylene glycol, 0.1 to 20 percent of a bactericide, 1 to 3 percent of a nourishing agent and 56 to 92.4 percent of purified water with a pH value of 4 to 5. The physical contraception gel film-forming agent provided by the invention can wrap sperm and shield the sperm so that the sperm cannot pass through the cervical opening in a certain time, thereby achieving the purpose of pure physical contraception, and the contraceptive rate is higher; finally, the sperm is discharged out of the body along with vaginal secretion, and the physical contraception gel film-forming agent has no toxic or side effect on female physiological health; the physical contraception gel film-forming agent does not contain the spermicide, the action timeto the contraceptive gel is wider than that of the traditional contraceptive membrane; the physical contraception gel film-forming agent can prevent and improve the genital tract infection, can improve the defect that the external contraceptive is easy to be infected, and can adjust the pH value of the vagina, thereby achieving the effects of moisturizing, lubricating, improving the elasticity ofthe vagina, reducing the vagina and improving the quality of sexual life.

The utility model relates to a gynecological vaginal closer, and solves the problem that no special auxiliary training equipment for vaginal closure of postpartum women exists at the present stage, and consequently, the vaginal closure of the postpartum women is slow, and the risk of reproductive organ infection is easily caused. The gynecological vaginal closer comprises a bed frame; a placementgroove is formed in the right side of the bed frame; a rotatable frame plate is rotatably connected to the middle of the bed frame; a massage plate capable of moving left and right is slidably connected to the right side of the frame plate; a rotary disc is rotatably connected to the middle of the frame plate; a first massage column capable of being gathered and a second massage column capable ofvertically ascending and descending are rotatably connected to the rotary disc; a plurality of sets of massage blocks which are distributed in a mirror image mode and can move relatively are slidablyconnected to the left side of the frame plate, and clamping jaws which rotate synchronously are rotatably connected to the massage blocks; and the left side of the bed frame is slidably connected withtwo foot fixing plates with the adjustable distance.

The invention relates to beta-defensin 15 of specific antibacterial peptides of rat epididymis and application thereof, in particular to Defb15 genes of rats or orthologous genes thereof or application of amino acid sequences of the Defb15 genes or the orthologous genes thereof in the preparation of medicines for regulating and controlling male fertility, the development of male contraceptive medicines and the preparation of medicines for diagnosing and treating male infertility and resisting genital tract infection. The invention also relates to a medicinal composition containing the genes or the amino acid sequences.

The invention relates to the medical field, and discloses the usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases. According to clinical tests, human interferon has curative effects on HPV infection, and particularly has remarkable curative effects on simple type HPV infection and high-risk type HPV continuous genital tract infection. The usage of human interferon is significant to preventive treatment of HPV infection, particularly the simple type HPV infection, and prevention and reduction of cervical erosion and cervical cancers, and has bright clinical application prospect.

The invention relates to a complex microbial inoculant for preventing and treating reproductive tract infection. The complex microbial inoculant for preventing and treating reproductive tract infection comprises a Lactobacillus crispatus LCr86 strain and a Lactobacillus gasseri LG08 strain, wherein the Lactobacillus crispatus LCr86 strain and the Lactobacillus gasseri LG08 strain are used for preventing and treating reproductive tract infection. The complex microbial inoculant can prevent and / or treat genital tract infection related diseases, and can be applied to preparation of products for preventing and / or treating genital tract infection related diseases.

The invention discloses an external contraceptive capable of preventing and curing genital tract infection and a preparation method of the external contraceptive. The external contraceptive is prepared from the following raw materials in parts by weight: 10-40 parts of cortex phellodendri, 10-40 parts of ginkgo, 30-120 parts of black nightshade, 20-60 parts of dandelion, 3-120 parts of dahurian patrinia herb, 10-40 parts of dittany bark, 30-120 parts of glabrous greenbrier rhizome, 10-25 parts of mentha haplocalyx, 1.0-2.5 parts of borneol and 10-40 parts of tree peony bark. The external contraceptive not only can effectively prevent and cure genital tract infection, but also has the efficacy of killing sperms through external use. The external contraceptive has a vagina protection effect and moreover has the effects of preventing and curing genital tract inflammation and lubrication. The external contraceptive has a killing or restraining effect on common vagina pathogens and part of sexually transmitted infection pathogens, and has little influence on lactic acid bacteria. Compared with a conventional spermicide product for vaginal use, the external contraceptive causes fewer adverse reactions such as local stimulation.

The invention discloses a compound cefixime nano-emulsion antibacterial drug, which is formed by the following raw materials in mass percent: 23.0%-38.5% of surfactant, 3.0%-18.0% of oil, 0.2%-6.0% of cefixime, 0.05%-1.5% of probenecid and the balance of distilled water, wherein the sum of the mass percents of the raw materials is 100%. The compound cefixime nano-emulsion antibacterial drug is mainly used for treating bacterial infectious diseases, including respiratory tract diseases, urinary tract diseases, genital tract infections, otitis media, nasal sinusitis and scarlet fever, which are caused by streptococcus, pneumococcus, neisseria gonorrhoeae, bacillus coli, proteus and haemophilus influenza and the like. The compound cefixime nano-emulsion antibacterial drug has the advantages that: the nano-emulsion preparation is clear and transparent liquid and is good in stability, rapid in absorption and targeted in drug release, the problem of poor solubility of the nano-emulsion preparation in water is solved, the metabolic time of the nano-emulsion preparation in vivo is retarded, the consumption of adjuvants is reduced, and the production cost is lowered, so that the compound cefixime nano-emulsion antibacterial drug has broad market prospects in the medicine field.

The invention relates to the technical field of assisted reproduction of the breeding industry, in particular to a multi-tube insemination gun for insemination of horses and donkeys. The problem of possible genital tract infection of dams of horses and donkeys due to troublesome repeated insemination is solved. The multi-tube insemination gun for insemination of horses and donkeys consists of a stainless steel jacket, a movable five-hole rubber inner plug with certain elasticity, and an insemination gun push rod with five front push rod semen thin tubes. A plastic jacket with certain hardness and toughness can additionally sleeve on the stainless steel jacket and has effects of protecting the multi-tube insemination gun and guaranteeing sanitation, the inner plug is connected with the semen thin tubes in a sleeving manner during insemination and stops the semen from flowing backwards in the jacket, and the insemination gun push rod is used for holding the semen thin tubes and pushing the semen out of the thin tubes.

The invention belongs to the technical field of Tibetan yak breeding, and discloses a vaginal plug for yaks, an estrus promoting device for livestock, and an application method. After a vagina cottonat the front end of the vaginal plug for yaks is placed in the vagina, the vagina cotton absorbs liquid in the vagina to expand, and the volume of the vagina cotton is enlarged to 4-5 times; the vagina cotton after absorbing the liquid is attached to vagina mucosa, so that plug separating and adhering are avoided; and the diameter of the vaginal plug for yaks is 20mm-30mm, and the length of the vaginal plug for yaks is 40mm-48mm. Before the vaginal plug for yaks is placed in the vagina, the diameter of the vaginal plug for yaks is small, after being placed in the vagina, the vaginal plug for yaks can absorb the liquid in the vagina to expand, and the volume is enlarged to 4-5 times; the cotton plug after absorbing the liquid is soft in texture, and free from irritants to the vagina mucosanearly, so that the phenomena of plug separating and adhering are hardly generated; and the difficult problems of discomfort and stimulation of the yak vagina are solved, and in production, when the plug is withdrawn, the adhesion of the sponge plug and the vagina wall is overcome, and the genital tract infection rate is reduced.

The invention provides a lavage fluid for bacterial vaginitis, and by adopting the technical scheme, an obvious treatment effect is achieved through selection of traditional Chinese medicine and quantitative optimal design. Litsea cubeba has the effects of regulating qi, removing stasis, detoxifying and reducing swelling and is used as a main component, so as to achieve an obvious inhibiting effect on various pathogenic microorganisms; nervilia fordii has the effecct of clearing toxicity, and the bacteriostatic effect can be further increased by adding a reasonable amount of nervilia fordii in a formula; bittersweet is the whole herb, has the bitterly cold flavor, is in lung, liver and spleen channels and is favorable for alleviating the development of inflammation; in addition, rhizoma arisaematis has the effects of dispelling wind and relieving convulsion. According to the lavage fluid, the treatment effect and the treatment speed of the lavage fluid on the bacterial vaginitis can be obviously increased by adding a reasonable amount of corydalis amabilis, semen litchi, turmeric, epimedium and fenugreek on the basis of the components, and additionally, the complication probability of the upper genital tract infection can be reduced.

The invention belongs to the technical field of medical instruments, discloses a gynecological examination dosing and sampling integrated device and a control method thereof. The gynecologic examination dosing and sampling integrated device comprises a patient information acquisition module, a physiological data acquisition module, an ultrasonic image acquisition module, a central control module,a blood drawing module, a blood analysis module, a secretion sampling module, a secretion detection module, a symptom diagnosis module, a dosing module, a data storage module, a terminal module and anupdating display module. By means of the blood analysis module, the problems that missed diagnosis is likely to happen, the detection cost is too high, the false positive rate is not synchronous withfemale genital tract infection in the prior art can be effectively solved, and compared with the prior art, the device is high in accuracy and low in cost; and meanwhile, the secretion detection module is used for accurately screening out a diagnosis result of an inspection result as a data analysis result, so that the accuracy of data analysis is improved, the medical intelligence is realized, and the burden of medical personnel is reduced.

Provided is a method for treating and reducing the recurrence of genital tract infections such as gonococcal infections. The method comprises local application of IL-12 incorporated in polymeric microspheres. The invention relates to compositions comprising IL-12 and methods for using such compositions for treatment of genital tract infections. Infections that can be treated by the present method include those that are caused by N. gonorrhoeae, C. trachomatis or both.

The invention provides a system and a grouping method for carrying out risk assessment on aerobic bacterial vaginitis by using gram staining smears and an establishment method of a prediction model adopted by the system and the grouping method. The systems and methods are based on the combination of vaginal secretion gram staining smears and clinical characteristics, can quickly and conveniently perform aerobic bacterial vaginitis risk assessment, and can provide a homogenized and standardized data basis for artificial intelligence reading of genital tract infection.

Provided is a method for treating and reducing the recurrence of genital tract infections such as gonococcal infections. The method comprises local application of IL-12 incorporated in polymeric microspheres. A method is also provided to reduce the incidence of genital tract infections caused by N. gonorrhoeae by administration of outer membrane vesicle preparations from N. gonorrhoeae and IL-12 incorporated in polymeric microspheres.

The invention discloses a preparation technology of bacteriostasis and equilibrium adsorption dry and comfortable fine hair for women, and relates to the technical field of preparation of adsorption dry and comfortable fine fire for bacteriostasis and balance of women and maintaining vagina of women. The adsorption dry and comfortable fine fire specially comprises the components of chitosan, chitosan fibers, chitosan oligosaccharide, collagen and a plant extract, wherein the collagen is flower collagen and the plant extract is a tea extract. The adsorption dry and comfortable fine hair prepared by the preparation technology adopts the chitosan and the collagen as core functional compositions. A modern production technology of the biological technology is adopted to prepare the bacteriostasis and equilibrium adsorption dry and comfortable fine hair, so that various pathogenic microorganisms for causing genital tract infection of women can be effectively killed.

The present invention discloses the use of 1, 4-naphthalene diphenol in preparing external use spermicidal contraceptive capable of preventing and treating genital tract infection and the external use spermicidal contraceptive prepared with 1, 4-naphthalene diphenol. The external use spermicidal contraceptive possesses triple functions of diminishing inflammation, birth control and improving sexual life. The spermicidal contraceptive has powerful spermicidal effect 25 times higher than that of nonoxynol nonylphenoxy-polyethoxyethanol, no bacteriostasis on normal lactobacillus inside vagina and effect of defending partial STD pathogens. It has the features of safety, high efficiency and convenience.

Provided is a method for treating and reducing the recurrence of genital tract infections such as gonococcal infections. The method comprises local application of IL-12 incorporated in polymeric microspheres. A method is also provided to reduce the incidence of genital tract infections caused by N. gonorrhoeae by administration of outer membrane vesicle preparations from N. gonorrhoeae and IL-12 incorporated in polymeric microspheres.

The invention belongs to the field of anti-infective medicines, and particularly relates to an antibacterial agent and beta-lactam enzyme inhibitor composition and an application thereof. The composition comprises A: mezlocillin or pharmaceutically-acceptable salt thereof, and preferably mezlocillin sodium; and B, avabatan or pharmaceutically-acceptable salt thereof, and preferably avabatan, wherein the mass ratio of the A to the B is (10-1) to (1-10). According to the composition disclosed by the invention, the mezlocillin is protected by the avabatan from being hydrolyzed by beta-lactamase,so that sterilizing effects can be reinforced, the problem that bacteria are drug resistant to the mezlocillin can be solved, and the composition can be used for preparing medicines for the respiratory system, the urinary system, the digestive system, department of gynecology and reproduction organ infection, caused by mezlocillin sensitive bacteria and beta-lactamase producing drug-resistance bacteria.

The invention discloses Lactobacillus flexus for preventing and treating women's urogenital tract infection. The Lactobacillus campus provided by the present invention is specifically Lactobacillus campus (Lactobacillus. Growth of other conditional pathogenic bacteria; at the same time, it has strong adhesion to vaginal epithelial cells, ensuring the colonization of bacterial strains in vaginal epithelial cells. The Lactobacillus.crispatus IMC-25 provided by the present invention has a certain application prospect in the prevention and treatment of urogenital tract infection.